ArticleCureus2025
Assessment of HIF-1α and c-MYC in Breast Carcinoma and Their Association With Clinicopathological Parameters: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer is one of the most common malignancies. Early diagnosis and prevention usually lead to a good prognosis and a better survival rate. Despite significant advancements in the prevention, there is still a lack of effective therapies against particular subtypes. A complex interplay takes place between HIF-1α (hypoxia-inducible factor 1-alpha) and MYC, which reprograms the metabolism of cancer cells and promotes tumour cell growth, progression, and therapy resistance.
aimTo study the immunohistochemical expression of HIF-1α and c-MYC in breast carcinoma cases and their correlation with clinicopathological parameters like age, tumour grade, tumour stage, nodal status and molecular subtypes, lymphovascular invasion, and perineural invasion, and their association with each other. MATERIALS AND
methodsA total of 61 cases of histopathologically confirmed invasive breast carcinoma were studied. Clinical and paraclinical characteristics were recorded. Immunohistochemistry for HIF-1α and c-MYC was done. HIF-1α expression was categorised as negative, low, and high, while c-MYC expression was scored as negative and positive. The data were analysed using univariate description and bivariate analysis, applying the chi-square test.
resultThe age ranged from 31 to 81 years, with a mean of 52.9 ± 12.9 years. HIF-1α expression was significantly correlated with the grade of the tumour (p = 0.035). However, no significant association was obtained between HIF-1α and age, lymphovascular invasion (LVI), perineural invasion (PNI), tumour stage, nodal status, proliferative index, and molecular subtypes. Our study did not find any significant correlation between c-MYC expression with histologic grade, LVI, PNI, tumour stage, nodal status, molecular subtypes, and HIF-1α expression.
conclusionAn increase in HIF-1α expression correlated with aggressive behaviour of cancer and a higher likelihood of metastatic tumours. HIF-1α inhibitors can be considered as a newer therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.